Signals, Powered By EquityPandit
Cadila Healthcare has received approval from the US health regulator, for Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg and 500 mg.
These tablets will be suggested for treating ongoing high levels of iron in the body, caused by multiple blood transfusions and also to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions.
Further, the tablets will manufactured at the existing facility in SEZ, Ahemdabad and with this approval, the company now has 202 approvals from the FDA.
